Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
Farsang C, Athyros V, Gaw A; ACTFAST-2 investigators and Steering Committee members. Farsang C, et al. Curr Med Res Opin. 2007 Aug;23(8):1945-56. doi: 10.1185/030079907X223242. Curr Med Res Opin. 2007. PMID: 17626713
OBJECTIVES: ACTFAST-2 was designed to match the starting dose of a statin to the baseline low density lipoprotein-cholesterol (LDL-C) value, to allow high-risk European subjects to achieve LDL-C targets within 12 weeks with the initial dose or one up-titration. ...The tota …
OBJECTIVES: ACTFAST-2 was designed to match the starting dose of a statin to the baseline low density lipoprotein-cholesterol (LDL-C) …
How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.
Leiter LA, Martineau P, de Teresa E, Farsang C, Gaw A, Gensini G, Langer A; ACTFAST 1 & 2 investigators. Leiter LA, et al. J Fam Pract. 2008 Oct;57(10):661-8. J Fam Pract. 2008. PMID: 18842192 Clinical Trial.
Among ST subjects, we observed reductions in LDL-C with atorvastatin beyond those achieved with other statins used at baseline in patients with diabetes and patients with metabolic syndrome. Atorvastatin was well tolerated. CONCLUSIONS: The ACTFAST studies confirm that a t …
Among ST subjects, we observed reductions in LDL-C with atorvastatin beyond those achieved with other statins used at baseline in patients w …